Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

CLX vs UL: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CLX Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 4–6 Matrix Metrics)

CLX Overall Winner 6-Pillar Tally: CLX 4 – 2 UL Matrix Metrics: CLX 4 – 6 UL

As of Nov 20, 2026, Clorox Company (CLX) is the stronger overall head-to-head candidate over Unilever plc (UL) in the Tradestie Institutional Equity Comparison Engine, winning 4–6 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). CLX carries a Unified Composite Score of 29.7/100 (SELL) at $104.73 (17.6x Forward P/E, 14.3% operating margin), whereas UL carries 46.7/100 (HOLD) at $63.82 (18.5x Forward P/E, 20.0% operating margin).

  • Composite vs. Pillar Nuance: While UL currently prints a higher short-term Unified Composite Score (46.7/100 HOLD vs. CLX 29.7/100 SELL), CLX captures the overall institutional head-to-head verdict (4–6 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (14.3% vs. 20.0% operating margin) and revenue trajectory (+33.3% vs. +0.5% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CLX vs UL
CLX NYSE Head-to-Head Winner
Clorox Company
Specialty Cleaning, Polishing And Sanitation Preparations
$104.73
-0.16% 1D
Market Cap $12.7B
TTM Revenue $7.20B
Forward P/E 17.6x
Beta / 30D Vol 0.43β · 37% Vol
Unified Composite Score
29.7 / 100 SELL
Tech 50.0 Fund 32.0 Flow 57.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 63
RSI-14: 62.9 · SMA20: $99.58 · SMA50: $90.45
UL NYSE
Unilever plc
Soap, Detergents, Cleang Preparations, Perfumes, Cosmetics
$63.82
+0.73% 1D
Market Cap $136.4B
TTM Revenue $50.6B
Forward P/E 18.5x
Beta / 30D Vol -0.03β · 24% Vol
Unified Composite Score
46.7 / 100 HOLD
Tech 47.0 Fund 45.0 Flow 50.0 Mom 36.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 45
RSI-14: 44.6 · SMA20: $65.54 · SMA50: $63.86

6-Pillar Scorecard Institutional Category Breakdown (CLX 4 – 2 UL)

Columns: Metric · CLX · UL
1. Valuation Multiples CLX
Forward P/E 17.6x 18.5x
Trailing P/E 18.9x 13.0x
PEG Ratio 1.62x 6.93x
EV / Revenue 2.5x 2.7x
2. Growth & Scale CLX
Revenue Growth (YoY) +33.3% +0.5%
Earnings Growth (YoY) +113.8% -5.6%
TTM Revenue (USD) $7.20B $50.6B
Market Cap $12.7B $136.4B
3. Profitability & Quality UL
Gross Margin 41.9% 47.1%
Operating Margin 14.3% 20.0%
Net Profit Margin 9.4% 18.3%
Return on Equity (ROE) 53.4% 31.9%
4. Balance Sheet & Cash Flow UL
Cash Generation (TTM) $453M $10.9B EBITDA
Cash Flow Margin 6.3% 21.5% EBITDA Mgn
Net Cash / Leverage $5.41B Net Debt $8.45 Book/Sh · 31.9% ROE
Dividend Yield 4.59% 3.24%
5. Options & Positioning CLX
Options Structure Phase SURGE UNCLASSIFIED
Current IV / %ile 44.8% (25th %ile) 13.8% (13th %ile)
Put/Call OI Skew 0.53x (Call-Skewed) Thin ADR Chain
OBV Trend / Tech Phase ACCUMULATION · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat CLX
OpEx & R&D Intensity 27.6% of Rev ($1.99B) 27.1% of Rev ($13.7B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Scale & Operating Efficiency Moat
Supply-Chain Role Household & Personal Products Operator Household & Personal Products Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CLX (4) vs UL (6)
Institutional Metric CLX UL Criterion Row Edge
Market Capitalization
Scale
$12.7B $136.4B Larger Scale UL
Trailing P/E Ratio
Valuation
18.9x 13.0x Lower Multiple UL
Forward P/E Ratio
Valuation
17.6x 18.5x Lower Multiple CLX
Revenue Growth (YoY)
Growth
+33.3% +0.5% Higher Growth CLX
Operating Margin (TTM)
Profitability
14.3% 20.0% Higher Margin UL
Net Profit Margin
Profitability
9.4% 18.3% Higher Margin UL
Return on Equity (ROE)
Capital Efficiency
53.4% 31.9% Higher ROE CLX
52-Week Range Position
Momentum
51% ($79–$129) 45% ($55–$75) Stronger Trend CLX
Beta / 30D Volatility
Risk Regime
0.43β · 37% Vol -0.03β · 24% Vol Lower Realized Risk UL
Unified Institutional Score
Composite Signal
29.7 / 100 (SELL) 46.7 / 100 (HOLD) Higher Composite UL
Trailing 12M Revenue (USD)
Operating Scale
$7.20B $50.6B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
41.9% 47.1% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.62x PEG · 2.5x EV/Rev 6.93x PEG · 2.7x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$453M ($5.41B Net Debt) $10.9B EBITDA ($8.45 Book/Sh · 31.9% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CLX +22.88 pp
CLX: +18.13% · UL: -4.75%
3M Horizon Tie
CLX: -2.28% · UL: -2.3%
6M Horizon UL +1.17 pp
CLX: +10.11% · UL: +11.28%
1Y Horizon UL +2.01 pp
CLX: +6.4% · UL: +8.41%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CLX vs UL. Trailing 12-month operating profitability (CLX 14.3% vs UL 20.0%) and valuation multiples (CLX 17.6x vs UL 18.5x Forward P/E) are benchmarked directly in Pillar 4 below.

CLX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$7.20B
Gross Margin41.9%
Op. Margin14.3%
ROE / Fwd P/E53.4% · 17.6x
UL ADR TTM Benchmark FX-Normalized USD
TTM Revenue$50.6B
Gross Margin47.1%
Op. Margin20.0%
ROE / Fwd P/E31.9% · 18.5x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CLX SURGE
5d in phase · OBV ACCUMULATION
Current IV 44.8%
IV Percentile 25th %ile
Put/Call OI Skew 0.53x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact CLX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
UL UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 13.8%
IV Percentile 13th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact UL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $110.17 · IV 35.9%

CLX Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($11,017)

Compare $11,017 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 35.9% ATM IV.

5-DAY BULLISH SWING Liq A

Dec 18 $110 / $115 Bull Call Spread

Buy 1x $110C · Sell 1x $115C · 31d

Net Entry $223 Debit
T+5d @ +5% Move +$93 (+42%)
Max Risk / Buffer $223 Capped
5d Edge & Liquidity 0.8x R:R · Liq A
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq B

Dec 18 $105 / $100 Bull Put Spread

Sell 1x $105P · Buy 1x $100P · 31d

Net Entry $120 Credit
Max Credit / Yield +$120 (+31.6% RoM)
Max Risk / Buffer -5.8% Cushion ($380 Mgn)
5d Edge & Liquidity 71% PoP · Liq B
Simulate 5-Day Payoff →
5-DAY DOWNSIDE SPREAD Liq C

Dec 18 $110 / $105 Bear Put Spread

Buy 1x $110P · Sell 1x $105P · 31d

Net Entry $205 Debit
T+5d @ -5% Drop +$102 (+50%)
Max Risk / Buffer $205 Capped
5d Edge & Liquidity 0.9x R:R · Liq C
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CLX Moat Profile High-Margin Pricing Power Moat
Household & Personal Products Operator
Competes within the Household & Personal Products value chain with $12.7B market capitalization and 14.3% operating margin.
OpEx & R&D Reinvestment 27.6% of Rev ($1.99B)
90D Engineering Disclosures 0 Published
UL Moat Profile Scale & Operating Efficiency Moat
Household & Personal Products Operator
Competes within the Household & Personal Products value chain with $136.4B market capitalization and 20.0% operating margin.
OpEx & R&D Reinvestment 27.1% of Rev ($13.7B)
90D Engineering Disclosures 0 Published

Investor FAQ CLX vs UL Key Questions & Quantitative Answers

As of Nov 20, 2026, Clorox Company (CLX) is the stronger overall head-to-head candidate over Unilever plc (UL) in the Tradestie Institutional Equity Comparison Engine, winning 4–6 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). CLX carries a Unified Composite Score of 29.7/100 (SELL) at $104.73 (17.6x Forward P/E, 14.3% operating margin), whereas UL carries 46.7/100 (HOLD) at $63.82 (18.5x Forward P/E, 20.0% operating margin). Composite vs. Pillar Nuance: While UL currently prints a higher short-term Unified Composite Score (46.7/100 HOLD vs. CLX 29.7/100 SELL), CLX captures the overall institutional head-to-head verdict (4–6 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (14.3% vs. 20.0% operating margin) and revenue trajectory (+33.3% vs. +0.5% YoY).

CLX leads the Growth & Scale pillar: CLX posts +33.3% YoY revenue growth and +113.8% YoY earnings growth on $7.20B TTM revenue (41.9% gross margin, 14.3% operating margin), compared with UL at +0.5% YoY revenue growth and -5.6% YoY earnings growth on $50.6B TTM revenue (47.1% gross margin, 20.0% operating margin). On trailing 12-month operating scale, CLX generates $7.20B in USD-normalized revenue versus $50.6B for UL. In operating R&D and SG&A reinvestment, CLX deploys 27.6% of Rev ($1.99B) (0 90-day corporate R&D disclosures) versus 27.1% of Rev ($13.7B) (0 disclosures) for UL.

CLX screens cheaper on headline valuation multiples. CLX trades at 17.6x Forward P/E, 18.9x Trailing P/E, 1.62x PEG, and 2.5x EV/Revenue (6.3% FCF margin), whereas UL trades at 18.5x Forward P/E, 13.0x Trailing P/E, 6.93x PEG, and 2.7x EV/Revenue (21.5% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CLX (53.4% ROE) versus UL (31.9% ROE) capital efficiency.

In options market volatility and institutional positioning, CLX carries 44.8% implied volatility (25th %ile, Balanced (25th–60th %ile)), a 0.53x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a SURGE options structure phase (0.43β · 37% Vol realized risk). By comparison, UL carries 13.8% implied volatility (13th %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.03β · 24% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.